Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert J. Fischer is active.

Publication


Featured researches published by Robert J. Fischer.


Emerging Infectious Diseases | 2016

Nanopore Sequencing as a Rapidly Deployable Ebola Outbreak Tool

Thomas Hoenen; Allison Groseth; Kyle Rosenke; Robert J. Fischer; Andreas Hoenen; Seth Judson; Cynthia Martellaro; Darryl Falzarano; Andrea Marzi; R. Burke Squires; Kurt R. Wollenberg; Emmie de Wit; Joseph Prescott; David Safronetz; Trenton Bushmaker; Friederike Feldmann; Kristin L. McNally; Fatorma K. Bolay; Barry S. Fields; Tara K. Sealy; Mark Rayfield; Stuart T. Nichol; Kathryn C. Zoon; Moses Massaquoi; Vincent J. Munster; Heinz Feldmann

Rapid sequencing of RNA/DNA from pathogen samples obtained during disease outbreaks provides critical scientific and public health information. However, challenges exist for exporting samples to laboratories or establishing conventional sequencers in remote outbreak regions. We successfully used a novel, pocket-sized nanopore sequencer at a field diagnostic laboratory in Liberia during the current Ebola virus outbreak.


Emerging Infectious Diseases | 2015

Postmortem Stability of Ebola Virus

Joseph Prescott; Trenton Bushmaker; Robert J. Fischer; Kerri L. Miazgowicz; Seth Judson; Vincent J. Munster

The ongoing Ebola virus outbreak in West Africa has highlighted questions regarding stability of the virus and detection of RNA from corpses. We used Ebola virus–infected macaques to model humans who died of Ebola virus disease. Viable virus was isolated <7 days posteuthanasia; viral RNA was detectable for 10 weeks.


Emerging Infectious Diseases | 2015

Ebola Virus Stability on Surfaces and in Fluids in Simulated Outbreak Environments.

Robert J. Fischer; Seth Judson; Kerri L. Miazgowicz; Trenton Bushmaker; Joseph Prescott; Vincent J. Munster

We evaluated the stability of Ebola virus on surfaces and in fluids under simulated environmental conditions for the climate of West Africa and for climate-controlled hospitals. This virus remains viable for a longer duration on surfaces in hospital conditions than in African conditions and in liquid than in dried blood.


PLOS Neglected Tropical Diseases | 2012

Endemic Foci of the Tick-Borne Relapsing Fever Spirochete Borrelia crocidurae in Mali, West Africa, and the Potential for Human Infection

Tom G. Schwan; Jennifer M. Anderson; Job E. Lopez; Robert J. Fischer; Sandra J. Raffel; Brandi N. McCoy; David Safronetz; Nafomon Sogoba; Ousmane Maïga; Sekou F. Traore

Background Tick-borne relapsing fever spirochetes are maintained in endemic foci that involve a diversity of small mammals and argasid ticks in the genus Ornithodoros. Most epidemiological studies of tick-borne relapsing fever in West Africa caused by Borrelia crocidurae have been conducted in Senegal. The risk for humans to acquire relapsing fever in Mali is uncertain, as only a few human cases have been identified. Given the high incidence of malaria in Mali, and the potential to confuse the clinical diagnosis of these two diseases, we initiated studies to determine if there were endemic foci of relapsing fever spirochetes that could pose a risk for human infection. Methodology/Principal Findings We investigated 20 villages across southern Mali for the presence of relapsing fever spirochetes. Small mammals were captured, thin blood smears were examined microscopically for spirochetes, and serum samples were tested for antibodies to relapsing fever spirochetes. Ornithodoros sonrai ticks were collected and examined for spirochetal infection. In total, 11.0% of the 663 rodents and 14.3% of the 63 shrews tested were seropositive and 2.2% of the animals had active spirochete infections when captured. In the Bandiagara region, the prevalence of infection was higher with 35% of the animals seropositive and 10% infected. Here also Ornithodoros sonrai were abundant and 17.3% of 278 individual ticks tested were infected with Borrelia crocidurae. Fifteen isolates of B. crocidurae were established and characterized by multi-locus sequence typing. Conclusions/Significance The potential for human tick-borne relapsing fever exists in many areas of southern Mali.


PLOS Pathogens | 2014

Inactivation of Genes for Antigenic Variation in the Relapsing Fever Spirochete Borrelia hermsii Reduces Infectivity in Mice and Transmission by Ticks

Sandra J. Raffel; James M. Battisti; Robert J. Fischer; Tom G. Schwan

Borrelia hermsii, a causative agent of relapsing fever of humans in western North America, is maintained in enzootic cycles that include small mammals and the tick vector Ornithodoros hermsi. In mammals, the spirochetes repeatedly evade the host’s acquired immune response by undergoing antigenic variation of the variable major proteins (Vmps) produced on their outer surface. This mechanism prolongs spirochete circulation in blood, which increases the potential for acquisition by fast-feeding ticks and therefore perpetuation of the spirochete in nature. Antigenic variation also underlies the relapsing disease observed when humans are infected. However, most spirochetes switch off the bloodstream Vmp and produce a different outer surface protein, the variable tick protein (Vtp), during persistent infection in the tick salivary glands. Thus the production of Vmps in mammalian blood versus Vtp in ticks is a dominant feature of the spirochete’s alternating life cycle. We constructed two mutants, one which was unable to produce a Vmp and the other was unable to produce Vtp. The mutant lacking a Vmp constitutively produced Vtp, was attenuated in mice, produced lower cell densities in blood, and was unable to relapse in animals after its initial spirochetemia. This mutant also colonized ticks and was infectious by tick-bite, but remained attenuated compared to wild-type and reconstituted spirochetes. The mutant lacking Vtp also colonized ticks but produced neither Vtp nor a Vmp in tick salivary glands, which rendered the spirochete noninfectious by tick bite. Thus the ability of B. hermsii to produce Vmps prolonged its survival in blood, while the synthesis of Vtp was essential for mammalian infection by the bite of its tick vector.


Clinical Infectious Diseases | 2016

Plasmodium Parasitemia Associated With Increased Survival in Ebola Virus–Infected Patients

Kyle Rosenke; Jennifer Adjemian; Vincent J. Munster; Andrea Marzi; Darryl Falzarano; Clayton O. Onyango; Melvin Ochieng; Bonventure Juma; Robert J. Fischer; Joseph Prescott; David Safronetz; Victor Omballa; Collins Owuor; Thomas Hoenen; Allison Groseth; Cynthia Martellaro; Galina E. Zemtsova; Joshua S. Self; Trenton Bushmaker; Kristin L. McNally; Thomas Rowe; Shannon L. Emery; Friederike Feldmann; Brandi N. Williamson; Sonja M. Best; Tolbert Nyenswah; Allen Grolla; James E. Strong; Gary P. Kobinger; Fatorma K. Bolay

BACKGROUND The ongoing Ebola outbreak in West Africa has resulted in 28 646 suspected, probable, and confirmed Ebola virus infections. Nevertheless, malaria remains a large public health burden in the region affected by the outbreak. A joint Centers for Disease Control and Prevention/National Institutes of Health diagnostic laboratory was established in Monrovia, Liberia, in August 2014, to provide laboratory diagnostics for Ebola virus. METHODS All blood samples from suspected Ebola virus-infected patients admitted to the Médecins Sans Frontières ELWA3 Ebola treatment unit in Monrovia were tested by quantitative real-time polymerase chain reaction for the presence of Ebola virus and Plasmodium species RNA. Clinical outcome in laboratory-confirmed Ebola virus-infected patients was analyzed as a function of age, sex, Ebola viremia, and Plasmodium species parasitemia. RESULTS The case fatality rate of 1182 patients with laboratory-confirmed Ebola virus infections was 52%. The probability of surviving decreased with increasing age and decreased with increasing Ebola viral load. Ebola virus-infected patients were 20% more likely to survive when Plasmodium species parasitemia was detected, even after controlling for Ebola viral load and age; those with the highest levels of parasitemia had a survival rate of 83%. This effect was independent of treatment with antimalarials, as this was provided to all patients. Moreover, treatment with antimalarials did not affect survival in the Ebola virus mouse model. CONCLUSIONS Plasmodium species parasitemia is associated with an increase in the probability of surviving Ebola virus infection. More research is needed to understand the molecular mechanism underlying this remarkable phenomenon and translate it into treatment options for Ebola virus infection.


Emerging Infectious Diseases | 2016

Ebola Virus Persistence in Semen Ex Vivo

Robert J. Fischer; Seth Judson; Kerri L. Miazgowicz; Trent Bushmaker; Vincent J. Munster

On March 20, 2015, a case of Ebola virus disease was identified in Liberia that most likely was transmitted through sexual contact. We assessed the efficiency of detecting Ebola virus in semen samples by molecular diagnostics and the stability of Ebola virus in ex vivo semen under simulated tropical conditions.


Ticks and Tick-borne Diseases | 2014

First isolation of the relapsing fever spirochete, Borrelia hermsii, from a domestic dog

Ashley L. Kelly; Sandra J. Raffel; Robert J. Fischer; Michael Bellinghausen; Connie Stevenson; Tom G. Schwan

In North America, tick-borne relapsing fever of humans is most frequently caused by infection with the spirochete Borrelia hermsii. Prior to our investigation, this spirochete was not known to infect dogs although another species, Borrelia turicatae, has been isolated from domestic canids in Florida and Texas. A clinically ill dog in Washington, USA, was spirochetemic upon examination. Spirochetes were isolated from the dogs serum and examined by PCR and multi-locus sequence typing. DNA sequences for 7 loci all typed the spirochete as B. hermsii and a member of genomic group II of this species. Therefore, companion dogs that reside in rustic cabins in higher elevation forests are at risk of infection with B. hermsii.


Emerging Infectious Diseases | 2016

The Merits of Malaria Diagnostics during an Ebola Virus Disease Outbreak

Emmie de Wit; Darryl Falzarano; Clayton O. Onyango; Kyle Rosenke; Andrea Marzi; Melvin Ochieng; Bonventure Juma; Robert J. Fischer; Joseph Prescott; David Safronetz; Victor Omballa; Collins Owuor; Thomas Hoenen; Allison Groseth; Galina E. Zemtsova; Joshua S. Self; Trenton Bushmaker; Kristin L. McNally; Thomas Rowe; Shannon L. Emery; Friederike Feldmann; Brandi N. Williamson; Tolbert Nyenswah; Allen Grolla; James E. Strong; Gary P. Kobinger; Ute Stroeher; Mark Rayfield; Fatorma K. Bolay; Kathryn C. Zoon

Malaria is a major public health concern in the countries affected by the Ebola virus disease epidemic in West Africa. We determined the feasibility of using molecular malaria diagnostics during an Ebola virus disease outbreak and report the incidence of Plasmodium spp. parasitemia in persons with suspected Ebola virus infection.


Emerging Infectious Diseases | 2015

Tickborne Relapsing Fever, Bitterroot Valley, Montana, USA

Joshua Christensen; Robert J. Fischer; Brandi N. McCoy; Sandra J. Raffel; Tom G. Schwan

Persons in this region are at risk for acquiring this disease.

Collaboration


Dive into the Robert J. Fischer's collaboration.

Top Co-Authors

Avatar

Vincent J. Munster

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Trenton Bushmaker

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

David Safronetz

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Tom G. Schwan

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Joseph Prescott

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Emmie de Wit

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Friederike Feldmann

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Sandra J. Raffel

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Allison Groseth

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Andrea Marzi

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge